• The XEN 63 Solution Implant is intended to reduce intraocular pressure (IOP) in patients with primary open angle glaucoma ¹
• XEN 63 is a minimally invasive, micro-incisional glaucoma surgery designed to lower IOP ²
• XEN 63 Gel Implant provides innovative treatment option for Canadians impacted by glaucoma  

MONTREAL , Sept. 27, 2022 /CNW/ –  AbbVie (NYSE: ABBV) announced today the availability of the XEN ^® 63 Solution Implant, the surgical implant designed to lower high eye stress in open up angle glaucoma sufferers, exactly where previous medical treatment options have unsuccessful. ¹   The XEN 63 Skin gels Implant is an additional strategy to surgeons, clinically proven in order to reduce intraocular pressure (IOP) in individuals with main open position glaucoma. ³

“I see the impact of glaucoma on patients’ quality associated with life every day in my practice. Glaucoma typically damages the peripheral vision first, so it often goes unnoticed by sufferers as the disease worsens. That’s why glaucoma is known as the silent thief of sight, ” said Dr. David Yan , Ophthalmologist-in-Chief, Mount Sinai Hospital, University of Toronto and Glaucoma Service Director, Kensington Eye Institute. “XEN 63 Gel Implant offers patients a new surgical option to decrease intraocular pressure when healthcare therapy cannot  adequately control the illness and renewed hope to prevent optic nerve damage. ”

XEN 63 is a gel implant consisting of a small 6mm long tube, delivered via a micro-incisional glaucoma surgical treatment. ^{one , 2}   It creates a brand new fluid outflow channel using a similar principle to conventional trabeculectomy, but allows fluid in order to bypass the particular impaired trabecular meshwork, the drainage system that becomes impaired in glaucoma. ^{2 , 4}

“Glaucoma affects more than 728, 000 Canadians. It is one associated with the leading causes of preventable blindness. Anyone can develop glaucoma but there are several different factors that can increase your risk of developing the condition, ” stated Doug Earle , President and CEO of Fighting Blindness North america. “It’s both exciting plus important to observe new, innovative treatment options being approved that could have the positive effect on Canadians living along with primary open angle glaucoma. ”

“As a leader within Eye Care in Europe , we are committed to help preserve and protect people’s vision through innovating and addressing the greatest unmet needs in glaucoma, ” says Tracey Ramsay , Vice President and General Manager, AbbVie Nova scotia. “Today, we’re pleased to launch the XEN 63 Gel Implant plus offer a minimally invasive solution with regard to uncontrolled major open angle glaucoma. inch

The glaucoma treatment spectrum extends from pharmacotherapy involving topical medications (eye drops) as the particular first-line therapy to traditional, invasive filtration surgeries, such as trabeculectomy and aqueous shunt implantation. ^{5, 6, 7} Common challenges associated with pharmacotherapy include ineffective use (e. g., incorrect dose timing or even administration), ^{8 , 9} local or systemic side effects (e. g., irritation) or toxicity, ^{10, 11} and considerable lifetime costs. ¹² Filtration surgical options are typically used in advanced glaucoma cases or when targeting the very low intraocular stress as a treatment outcome. ¹³ These intrusive surgeries may be considered for medically refractory instances, or whenever there are usually such issues as intolerable side effects or even from ineffective use of medicines. ¹⁴

About Glaucoma

Glaucoma affects more than 728, 000 Canadians and takes the form of several related disease types, the most common being open up angle glaucoma. ¹⁵ Glaucoma is characterized by a build-up associated with aqueous humour fluid plus increased intraocular pressure (IOP) that problems the optic nerve. ¹⁵ There is no cure regarding glaucoma, but early detection and therapy can help avoid damage to the particular optic neural, and as a result, save vision. ¹⁵  

About XEN 63

XEN is a gel implant consisting of a small 6mm long pipe, delivered via a micro-incisional glaucoma surgery, which is intended to reduce intraocular pressure inside patients along with primary open angle glaucoma where previous treatments have failed. ¹ The XEN purification procedure creates a new fluid output channel using a similar principle to trabeculectomy, but enables fluid in order to bypass the impaired trabecular meshwork. ^{2, a few} XEN will be inserted through an ab-interno approach ¹ (from within the particular anterior chamber) and allows aqueous humor to flow out from the anterior chamber in to the subconjunctival space, minimizing tissue disruption seen with trabeculectomy or traditional glaucoma drainage implants. ^{1, 3, 16}   XEN 63 consists of a small tube that is 6mm long. ^one The inner diameter associated with XEN63 is usually 63µm and the external diameter is 170µm. ¹ XEN63 has an outflow resistance of 2-3mmHg. ⁶ XEN63 was developed to boost the aqueous humor flow rate along with the intention of potentially providing decrease IOPs.  

About AbbVie

AbbVie’s mission is to discover and deliver revolutionary medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to possess a remarkable impact on people’s lives across a number of key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca . Follow @abbviecanada upon Twitter plus Instagram , or find us on LinkedIn.

SOURCE AbbVie Canada

For further info: Media: Muriel Haraoui, AbbVie Canada, 514-717-3764, [email protected]